vimarsana.com
Home
Live Updates
Theralink® Announces Promising Interim Results on the I
Theralink® Announces Promising Interim Results on the I
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board -November 03, 2023 at 09:16 am EDT
Golden, Colorado, Nov. 03, 2023 -- Theralink Technologies, Inc. , a precision oncology company with its exclusive commercial RPPA technology that can help predict which FDA-approved drug is...
Related Keywords
Chicago ,
Illinois ,
United States ,
Colorado ,
Trevor Mccartney ,
Exchange Commission ,
Inova Schar Cancer Institute ,
Gastrointestinal Cancer Program ,
Nasdaq ,
Securities Exchange ,
Holdings Inc ,
Theralink Technologies Inc ,
Globenewswire Inc ,
Schar Cancer Institute ,
Molecular Tumor Board ,
Inova Schar Molecular Tumor ,
Schar Cancer ,
Chief Executive Officer ,
Inova Molecular Tumor Board ,
Reverse Phase Protein Array ,
Securities Act ,
Securities Exchange Act ,
Merger Agreement ,
Quarterly Reports ,
Current Reports ,
Annual Reports ,
Multi Omic Data ,
Molecular Tumor Board Reveals ,
Inhibitor Resistance ,
Patient With Inflammatory Myofibroblastic ,
Markets ,